Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications

Protein Science

Volumn 18, Issue 7, 2009, Pages 1425-1438

  Fleury, Maxime J J ^a,b   Touzé, Antoine ^a,b   Maurel, Marie Christine ^c   Moreau, Thierry ^a   Coursaget, Pierre ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b Agents Transmissibles et Infectiologie ^*  (France)

^c CNRS   (France)

Author keywords

Bacterial surface display; Conformational epitope; HPV31; L1 protein; Neutralization

Indexed keywords

CAPSID PROTEIN; EPITOPE; HEPARAN SULFATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; BACTERIAL MEMBRANE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; EPITOPE MAPPING; ESCHERICHIA COLI; EXTRACELLULAR MATRIX; HUMAN PAPILLOMAVIRUS TYPE 31; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF; SURFACE PLASMON RESONANCE; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS NEUTRALIZATION;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CAPSID PROTEINS; EPITOPE MAPPING; EXTRACELLULAR MATRIX; HEPARITIN SULFATE; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; VIRION; VIRUS ATTACHMENT;

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 31; MIRIDAE;

EID: 67650090500     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.156     Document Type: Article

References (71)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
3. Ault KA, Future II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868.
4. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
5. He RT, Innis BL, Nisalak A, Usawattanakul W, Wang S, Kalayanarooj S, Anderson R (1995) Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45:451-461.
6. Klasse PJ, Sattentau QJ (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83:2091-2108.
7. Law M, Hangartner L (2008) Antibodies against viruses: passive and active immunization. Curr Opin Immunol 20:486-492.
8. Chomont N, Hocini H, Gody JC, Bouhlal H, Becquart P, Krief-Bouillet C, Kazatchkine M, Bélec L (2008) Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology 370:246-254.
9. Virgin HW 4th, Mann MA, Tyler KL (1994) Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases. J Virol 68:6719-6729.
10. Zhuge W, Jia F, Mackay G, Kumar A, Narayan O (2001) Antibodies that neutralize SIV(mac)251 in T lymphocytes cause interruption of the viral life cycle in macrophages by preventing nuclear import of viral DNA. Virology 287:436-445.
11. Varghese R, Mikyas Y, Stewart PL, Ralston R (2004) Postentry neutralization of adenovirus type 5 by an anti-hexon antibody. J Virol 78:12320-12332.
12. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR (1995) Immunization with viruslike particles from cotton-tail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959-3963.
13. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553-11557.
14. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW (1996) Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70:960-965.
15. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU (2001) Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291:324-334.
16. Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P (2003) Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their immunogenicity and delineates a conformational neutralizing epitope. Virology 309:32-40.
17. Orozco JJ, Carter JJ, Koutsky LA, Galloway DA (2005) Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 L1 capsomers. J Virol 79:9503-9514.
18. Yaegashi N, Jenison SA, Valentine JM, Dunn M, Taichman LB, Baker DA, Galloway DA (1991) Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol 65:1578-1583.
19. Volpers C, Sapp M, Snijders PJ, Walboomers JM, Streeck RE (1995) Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. J Gen Virol 76:2661-2667.
20. Heino P, Skyldberg B, Lehtinen M, Rantala I, Hagmar B, Kreider JW, Kirnbauer R, Dillner J (1995) Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 76:1141-1153.
21. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS (1996) Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224:477-486.
22. Christensen ND, Kirnbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW (1994) Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205:329-335.
23. Rose RC, Reichman RC, Bonnez W (1994) Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75:2075-2079.
24. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA (1998) In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 72:959-964.
25. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA (1999) Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73:4882-4889.
26. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565-1570.
27. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857-861.
28. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810-5822.
29. Combita AL, Touzé A, Bousarghin L, El Mehdaoui S, Sizaret PY, Muñoz N, Coursaget P (2001) Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and required cell surface heparan sulfate. FEMS Microbiol Lett 204:183-188.
30. Selinka HC, Giroglou T, Sapp M (2002) Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299:279-287.
31. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, Makarov VA, Sapp M (2007) Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81:10970-10980.
32. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77:12961-12967
33. Rommel O, Dillner J, Fligge C, Bergsdorf C, Wang X, Selinka HC, Sapp M (2005) Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol 75:114-121.
34. Bousarghin L, Touzé A, Combita-Rojas AL, Coursaget P (2003) Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol 84:157-164.
35. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M (2007) Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem 282:27913-27922.
36. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND (2006) Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80:8940-8950.
37. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449-2456.
38. Bousarghin L, Touzé A, Sizaret PY, Coursaget P (2003) Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol 77:3846-3850.
39. Smith JL, Campos SK, Ozbun MA (2007) Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 81:9922-9931.
40. Carpentier GS, Fleury MJ, Touzé A, Sadeyen JR, Tourne S, Sizaret PY, Coursaget P (2005) Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. J Med Virol 77:558-565.
41. Fleury MJ, Touzé A, Alvarez E, Carpentier G, Clavel C, Vautherot JF, Coursaget P (2006) Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151:1511-1523.
42. Rockberg J, Löfblom J, Hjelm B, Uhlén M, Ståhl S (2008) Epitope mapping of antibodies using bacterial surface display. Nat Methods 5:1039-1045.
43. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT (2007) Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 81:8784-8792.
44. Touzé A, Mahé D, El Mehdaoui S, Dupuy C, Combita-Rojas AL, Bousarghin L, Sizaret PY, Coursaget P (2000) The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity. FEMS Microbiol Lett 189:121-127.
45. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557-567.
46. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA (2003) Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 77:11625-11632.
47. Roth SD, Sapp M, Streeck RE, Selinka HC (2006) Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J 3:83.
48. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
49. Modis Y, Trus BL, Harrison SC (2002) Atomic model of the papillomavirus capsid. EMBO J 21:4754-4762.
50. Ludmerer SW, Benincasa D, Mark GE, III, Christensen ND (1997) A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 71:3834-3839.
51. Ludmerer SW, Benincasa D, Mark GE, III (1996) Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 70:4791-4794.
52. McClements WL, Wang XM, Ling JC, Skulsky DM, Christensen ND, Jansen KU, Ludmerer SW (2001) A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 89:262-268.
53. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomavirus. J Virol 76:6480-6486.
54. Rizk RZ, Christensen ND, Michael KM, Müller M, Sehr P, Waterboer T, Pawlita M (2008) Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89:117-129.
55. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC (2001) Immunological analyses of human papillomavirus capsids. Vaccine 19:1783-1793.
56. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199:926-935.
57. Moore JP, Sodroski J (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70:1863-1872.
58. Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM (2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81:1680-1689.
59. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
60. Wang Z, Christensen N, Schiller JT, Dillner J (1997) A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78:2209-2215.
61. Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ (1989) Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. J Gen Virol 70:2973-2987.
62. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
63. Kulski JK, Sadlei JW, Kelsall SR, Cicchini MS, Shellam G, Peng SW, Qi YM, Galloway DA, Zhou J, Frazer IH (1998) Type specific and genotype cross reactive B 20 epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies. Virology 243:275-282.
64. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS (2007) Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 282:31803-31811.
65. Fleury MJ, Touzé A, de Sanjosé S, Bosch FX, Klaustermeiyer J, Coursaget P (2008) Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol 15:172-175.
66. Lopez TV, Cancio C, Cruz-Talonia F, Ruiz B, Sapp M, Rocha-Zavaleta L (2008) Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from pateints with low-grade squamous intraepithelial lesions but not from cervical cancer patients. FEMS Immunol Med Microbiol 54:167-176.
67. Belnap DM, Olson NH, Cladel NM, Newcomb WW, Brown JC, Kreider JW, Christensen ND, Baker TS (1996) Conserved features in papillomavirus and polyomavirus capsids. J Mol Biol 259:249-263.
68. Touzé A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P (1998) The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 36:2046-2051.
69. Lu Z, Murray KS, Van Cleave V, LaVallie ER, Stahl ML, McCoy JM (1995) Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology (NY) 13:366-372.
70. James LC, Roversi P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299:1362-1367.
71. Morgenstern B (1999) DIALIGN 2: improvement of the segment-to-segment approach to multiple sequence alignment. Bioinformatics 15:211-218.